April 10, 2018 / 12:04 PM / 4 months ago

BRIEF-Kadmon Receives FDA Guidance On Pivotal Clinical Trial Design For KD025 In Chronic Graft-Versus Host Disease

April 10 (Reuters) - Kadmon Holdings Inc:

* HOST DISEASE

* ARM, PIVOTAL PHASE 2 CLINICAL TRIAL TO SUPPORT POTENTIAL REGISTRATION OF KD025 IN CGVHD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below